Will Oscar Health report Q1 2026 MLR below 84%?

The 28% weighted average rate increase is the strongest argument for MLR improvement. However, the 2025 MLR of 87.4% requires a 350+ bps improvement just to hit 84%. Management's track record of missed profitability targets (FY2025 was supposed to be profitable) creates a credibility discount. The metal mix shift to bronze/gold changes cost dynamics unpredictably. Q1 is seasonally favorable (lower utilization) which helps, but risk adjustment estimation in Q1 can still produce adverse surprises. Slightly above coin-flip for YES.

Q1 is consistently the lowest MLR quarter for ACA insurers — lower utilization, deductibles reset, and new member mix typically skews healthier. Oscar's 28% rate increase, combined with a younger member pool (age 38, down 1 year), provides genuine pricing tailwind. The question is whether Q1 specifically can hit below 84%, not full-year. The 400K member churn (higher-cost passive enrollees leaving) may actually improve Q1 MLR as sicker members drop. The key risk is risk adjustment accrual — but Q1 accruals tend to be conservative. Probability leans YES for the Q1-specific question.

The 2025 Q4 MLR of 95.4% represents a catastrophic quarter. While Q1 should improve from that level, the FY2025 MLR of 87.4% is the better baseline. The question is whether a 350+ bps improvement (87.4% to below 84%) is achievable in one quarter. The rate increase helps, but the Medicaid redetermination population influx that drove 2025 losses may persist into 2026 as those members haven't yet cycled through their plan year. Management's profitability projection pattern — consistent over-optimism — suggests the MLR guide itself should be discounted. Near coin-flip.

The 28% rate increase is substantial and should mechanically improve the MLR in Q1. Management explicitly says Q1 will be the lowest MLR quarter. The 400K member rolloff removes non-paying members who likely carried higher costs. However, management credibility is poor — they guided profitability for 2025 and missed by $443M. The bronze-heavy mix adds uncertainty. Leaning slightly YES because Q1 seasonality and rate increases provide a tailwind, but not by much.

This is genuinely uncertain. The rate increase points to improvement, but the 2025 experience shows that risk adjustment can overwhelm pricing. The metal mix shift introduces new cost dynamics that have no historical precedent for Oscar at this scale. The CFO's admission that risk adjustment is 'the most difficult thing' suggests even internal estimates are unreliable. True coin-flip with low confidence.

Q1 for ACA insurers almost always has the lowest MLR due to deductible resets and seasonal patterns. Oscar specifically called out Q1 as the lowest quarter. The 28% rate increase on top of a younger membership should produce meaningful premium per member growth that outpaces medical costs, at least in Q1 before utilization ramps. The risk adjustment accrual in Q1 is typically a conservative starting estimate. I lean YES for Q1 specifically, though the full-year guide remains questionable.

28% rate increase plus Q1 seasonality should produce below-84% MLR. The question is Q1-specific, not full-year. Q1 is almost always the best quarter for health insurers. Slight lean toward YES.

Q1 is the best quarter for MLR due to deductible resets. The 28% rate increase provides significant pricing headroom. Even with the 2025 miss, Q1 2025 MLR was likely below 87.4% (the full-year average), suggesting Q1 2026 at below 84% is plausible with rate increases. The 400K member churn may actually help by removing high-cost enrollees.

The analysis strongly suggests uncertainty. Rate increases help but risk adjustment is unpredictable. Management has a credibility problem. Q1 seasonality is favorable. Net assessment is slightly above 50% given the rate increase tailwind, but low confidence given the risk adjustment wild card.